Cooley advised 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company that specializes in developing novel protein-based therapeutics, on its agreement to sell to GSK, a global biopharma company, for $950 million.
Key deals, decisions + trends
Cooley advised 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company that specializes in developing novel protein-based therapeutics, on its agreement to sell to GSK, a global biopharma company, for $950 million.